AzTrials
AzTrials

Anemia in Chronic Kidney DiseaseDASHENGNCT07098416

A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）

An observational study of Anemia in Chronic Kidney Disease, run by Wei Chen at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anemia in Chronic Kidney Disease
How many people
20,000 participants
Where
1 siteChina
Study dates
1 Aug 2025to 31 Aug 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Anemia in Chronic Kidney Disease

Who may be able to join

None listed.

Who cannot join

  • Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);
  • Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;
  • Incomplete critical data elements (including age, sex, or visit dates).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Wei Chen contact

8602087769673

chenwei99@mail.sysu.edu.cn

Zhong Zhong contact

8602087769673

zhongzh55@mail.sysu.edu.cn

China1 site

  • First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510080

    Zhong Zhong, 8602087769673, zhongzh55@mail.sysu.edu.cn

Other trials in China

About this study

Official title: An In-Depth Analysis of the Present Diagnostic and Therapeutic Landscape for Renal Anemia in China's Real-World Clinical Environment: A Multicenter Retrospective Cohort Investigation（DASHENG Study）

Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.

Read the detailed description

Anemia adversely affects the quality of life of CKD patients and increases the risk of CKD progression.

This study utilize data from approximately 20 medical centers across China. It aims to:

  1. Analyze the disease characteristics, current diagnostic and treatments in Chinese patients with CKD-anemia.
  2. Evaluate the safety and efficacy profiles of different drugs used for CKD-anemia.
  3. Explore the direct medical costs associated with CKD-anemia management within real-world clinical practice in China.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China.

    Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage.

    Measured: 20230101-20241231

  2. Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.)

    An analysis will be performed to assess the safety according to CTCAE 5.0 .

    Measured: 20230101-20241231

Secondary outcomes (2)

  1. Analyze the efficacy of different anemia drugs in CKD patients with anemia.

    Use the hemoglobin level to analyze the efficacy of different anemia drugs in CKD patients with anemia.

    Measured: 20230101-20241231

  2. Explore the economic burden of anemia in CKD patients

    Use the annual cost to explore the direct economic burden of anemia in CKD patients.

    Measured: 20230101-20241231

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2025
  2. Study start1 Aug 2025 (estimated)
  3. Primary completion31 Aug 2026 (estimated)
  4. Study completion31 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
20,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07098416
Sponsor's protocol ID
IIT-2025-121
Acronym
DASHENG
Status last verified
Jul 2025
First submitted
10 Jul 2025
Last updated
1 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Anemia in Chronic Kidney Disease, run by Wei Chen at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Wei Chen (8602087769673, chenwei99@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China. (time frame: 20230101-20241231). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07098416.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in